Name: INSIGHT MOLECULAR DIAGNOSTIC (IMDX) Stock
Brand: INSIGHT MOLECULAR DIAGNOSTIC
Rating: 4.5 (3 reviews)

IMDX Latest News, Press Relases and Analysis

All

Press Releases

24 days ago - By: Insight Molecular Diagnostics Inc.

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

a month ago - By: Insight Molecular Diagnostics Inc.

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

2 months ago - By: Insight Molecular Diagnostics Inc.

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

2 months ago - By: Insight Molecular Diagnostics Inc.

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring

4 months ago - By: Benzinga

Exploring Insight Molecular's Earnings Expectations

24 days ago - By: Benzinga - Mentions: OGN TACT QRHC BKKT ...

Earnings Scheduled For November 10, 2025

2 months ago - By: Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

3 months ago - By: Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

3 months ago - By: Insight Molecular Diagnostics Inc.

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

3 months ago - By: Insight Molecular Diagnostics Inc.

iMDx to Participate in NYC Investment Conferences September 8 - 11

4 months ago - By: Insight Molecular Diagnostics Inc.

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

4 months ago - By: Insight Molecular Diagnostics Inc.

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

4 months ago - By: Insight Molecular Diagnostics Inc.

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

4 months ago - By: Insight Molecular Diagnostics Inc.

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

5 months ago - By: Insight Molecular Diagnostics Inc.

INSIGHT MOLECULAR DIAGNOSTIC (IMDX) Stock News

IMDX Latest News, Press Relases and Analysis

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring

Exploring Insight Molecular's Earnings Expectations

Earnings Scheduled For November 10, 2025

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

iMDx to Participate in NYC Investment Conferences September 8 - 11

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing